<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734615</url>
  </required_header>
  <id_info>
    <org_study_id>CLSZ102X2101</org_study_id>
    <secondary_id>2015-004016-38</secondary_id>
    <nct_id>NCT02734615</nct_id>
  </id_info>
  <brief_title>Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers</brief_title>
  <official_title>A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the safety and tolerability, identify recommended doses and regimens for
      future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of
      LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients
      with locally advanced or metastatic ER+ breast cancer who have progressed after endocrine
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 14, 2016</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Day 1 - Day 28 of Cycle 1 (28 day cycle)</time_frame>
    <description>The dose escalation part of the study will be guided by well-established statistical methods/models to estimate the maximum tolerated doses (MTD)and/or recommended doses for expansion (RDE). Safety, pharmacokinetic and pharmacodynamics data will guide dose escalation decisions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Incidence and severity of adverse events, serious adverse events, clinical laboratory values, vital signs, ECGs, dose interruptions, dose reductions and dose intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Assessment of preliminary anti-tumor activity of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719. ORR is defined as the proportion of patients with a best overall response of complete response or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>3 years</time_frame>
    <description>Assessment of preliminary anti-tumor activity of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Assessment of preliminary anti-tumor activity of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>3 years</time_frame>
    <description>Assessment of preliminary anti-tumor activity of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of study medications</measure>
    <time_frame>1 cycle (28 day cycle)</time_frame>
    <description>Plasma concentration versus time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration under fasted condition and fed condition</measure>
    <time_frame>Up to 2 cycles (28 day cycle)</time_frame>
    <description>Plasma concentration versus time under fasted and fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Pharmacodynamic marker Estrogen receptor (ER)</measure>
    <time_frame>3 years</time_frame>
    <description>To assess pharmacodynamics effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Pharmacodynamic marker Progesterone receptor (PgR)</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the pharmacodynamic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Pharmacodynamic marker pS6</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the pharmacodynamic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameter AUC</measure>
    <time_frame>6 cycles (28 day cycle)</time_frame>
    <description>AUC = Area under curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter Cmax</measure>
    <time_frame>6 cycles (28 day cycle)</time_frame>
    <description>Cmax = Maximum observed plasma concentration after drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter Tmax</measure>
    <time_frame>6 cycles (28 day cycle)</time_frame>
    <description>Tmax = Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter Cmin</measure>
    <time_frame>6 cycles (28 day cycle)</time_frame>
    <description>Cmin = Minimum observed plasma concentration after drug administration</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Advanced or Metastatic ER+ Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get LSZ102 single agent during dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get LSZ102 in combination with LEE011 during dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get LSZ102 in combination with BYL719 during dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get LSZ102 single agent during dose expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get LSZ102 + LEE011 (LEE011 intermittent regimen) during dose expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get LSZ102 + LEE011 (LEE011 continuous regimen) during dose expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will get LSZ102 in combination with BYL719 during dose expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSZ102</intervention_name>
    <description>LSZ102</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>LEE011</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>ribociclib, Kisqali</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719</intervention_name>
    <description>BYL719</description>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>alpelisib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained prior to any procedures

          -  Histologically and/or cytologically confirmed diagnosis of ER+/HER2- breast cancer

          -  Advanced or metastatic breast cancer

          -  Must be able to swallow tablets and capsules

        Exclusion Criteria:

          -  Symptomatic CNS metastases

          -  Patients whose laboratory values do not meet protocol criteria

          -  Clinically significant cardiac disease

          -  Impaired gastrointestinal function (GI) or GI disease that may significantly alter the
             absorption of oral medications

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center SC - LSZ102X2101</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto ku</city>
        <state>Tokyo</state>
        <zip>135 8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LSZ102</keyword>
  <keyword>LEE011</keyword>
  <keyword>ribociclib</keyword>
  <keyword>Kisqali</keyword>
  <keyword>BYL719</keyword>
  <keyword>alpelisib</keyword>
  <keyword>ER+ breast cancer</keyword>
  <keyword>advanced ER+ breast cancer</keyword>
  <keyword>metastatic ER+ breast cancer</keyword>
  <keyword>SERD</keyword>
  <keyword>SERM</keyword>
  <keyword>fulvestrant</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>aromatase inhibitor</keyword>
  <keyword>ESR1</keyword>
  <keyword>mtESR1</keyword>
  <keyword>wtESR1</keyword>
  <keyword>estrogen receptor</keyword>
  <keyword>endocrine therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

